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Abstract
A complex combination of molecular pathways and cell interactions causes 
facioscapulohumeral muscular dystrophy (FSHD). Several new therapies pose a 
promising solution to this disease with no cure. This chapter aims to explain the 
genetics of facioscapulohumeral muscular dystrophy, and review the current clini-
cal trials for the treatment of FSHD.
Keywords: facioscapulohumeral muscular dystrophy, antisense oligonucleotide, 
decoy nucleic acid, novel therapies, genetics, trials
1. Introduction
1.1 Epidemiology
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common 
muscular dystrophies. Worldwide, its prevalence is up to 6.8 in 100,000 and in 
the United States, it is about 1 in 20,000. It affects men more than women because 
estrogens counteract the differentiation impairment of FSHD myoblasts without 
affecting cell proliferation or survival. Estrogen effects are mediated by estrogen 
receptor β (ERβ), which reduces chromatin occupancy and transcriptional activity 
of double homeobox 4 (DUX4) [1].
1.2 History
Facioscapulohumeral muscular dystrophy was first described by two French 
physicians, Louis Landouzy and Joseph Jules Dejerine, in the late 1800s [2]. Their 
description was based on a family that they had monitored for 11 years. In 1950, 
Tyler and Stephens described a family from Utah that included 1249 people span-
ning six generations. All were descendants of an affected individual who had 
migrated to Utah in 1840. Their findings confirmed the autosomal dominant 
inheritance pattern of FSHD. Clinical criteria were established by an international 
consortium in 1991. These criteria were as follows: onset of the disease in the facial 
or shoulder girdle muscles and sparing of the extraocular, pharyngeal, and lingual 
muscles and the myocardium, facial muscle weakness in more than 50% of affected 
family members, autosomal dominant inheritance in familial cases and evidence 
of myopathic disease from electromyography and muscle biopsy in at least one 
affected member, without biopsy features specific for alternative diagnoses.
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2. Genetics
Facioscapulohumeral muscular dystrophy is caused by the inappropriate expres-
sion of an early embryonic transcriptional activator, DUX4, in adult muscle, leading 
to cell death [3, 4]. The disease is autosomal dominant, although up to one-third of 
cases involve de novo mutations, so there may not be a family history. About 10% 
of these sporadic cases are attributed to new mutations and 20% are attributed to 
mosaicism [2].
The Double Homeobox Protein 4 (DUX4) is the embryonic transcriptional 
activator responsible for the disease. DUX4 induces changes in the expression of 
hundreds of genes that impact many interconnected pathways, making a relation-
ship between gene expression and muscle degeneration difficult to discern [2]. 
Evidence reveals a complex RNA-mediated process that prompts a robust immune 
attack on myocytes [4]. It is found in embryonic tissues and allows for apoptosis of 
cells during formation [5–7].
There are two types of FSHD: Type 1 and Type 2. Type 1 results from a contrac-
tion of the D4Z4 repeat. Type 2 is due to mutations in silencing proteins. Both cases 
lead to chromatin relaxation and aberrant expression of the DUX4 gene in skeletal 
muscle [8]. The entire D4Z4 region is normally hypermethylated (and therefore 
silenced), but FSHD is characterized by hypomethylation of D4Z4. There are also 
two polymorphic genes (4qA and 4qB) that are also required to produce the disease. 
4qA has the ability to be pathogenic and 4qB does not, so at least one 4qA allele is 
required to produce FSHD [2].
The 4qA allele contains a promoter region pLAM, which allows for the DUX4 
protein to be transcribed. The 4qB allele lacks pLAM, so the protein cannot be 
produced. Since there are two copies of chromosome 4 in a cell; AA, BB, or AB 
are possible, but the presence of at least one A allele is required to produce FSHD, 
regardless of the presence of Type 1 or Type 2 mutations. This makes FSHD a 
digenic disease, as two mutations are required to produce disease (A-allele plus 
Type 1 or Type 2 mutations) [8].
2.1 Type 1 FSHD
Type 1 FSHD affects 95% of FSHD patients. It is caused by shortening of 
the D4Z4 array, which leads to hypomethylation and chromatin relaxation. The 
D4Z4 array is a 3300 DNA base pair (3.3 kb) long repeat units on the long arm 
(q) of chromosome 4. Subtelomeric regions of 4q and 10q at both 4q35 and 10q26 
contain D4Z4 arrays, but only the locus at 4q35 results in FSHD [8]. There can be 
1–100 units of the D4Z4 repeat. FSHD is associated with an array of 1–10 units at 
4q35, although cases with 11 or slightly greater have been described. Patients carry-
ing 1–3 units are usually severely affected and often represent new mutations, while 
patients carrying 4–10 units are typically familial cases [9]. There is an approximate 
inverse relationship of residual repeat size to the severity of the disease and the 
age at onset. A high degree of variability of disease expression even in patients 
with fragments of the same size makes it impossible to predict disease severity and 
progression in a given individual based on genetics alone.
2.2 Type 2 FSHD
Type 2 FSHD affects 5% of FSHD patients. It is usually caused by a mutation 
in the epigenetic modifier gene SMCHD1 on chromosome 18, but 20% of FSHD2 
patients do not have an identified mutation in the SMCHD1 gene, so the cause 
of the hypomethylation is unknown. SMCHD1 provides instructions for making 
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a protein that normally hypermethylates the D4Z4 region. A mutation in this 
gene leads to haploinsufficiency or dominant negative mutations in SMCDH1 
protein, leading to a reduced binding of SMCHD1 protein to the D4Z4 repeat and 
consequently to a loss of epigenetic marks (methylation) in this region. Some 
patients with Type 1 mutation can also have a Type 2 mutation, which worsens the 
disease [10].
3. Clinical manifestations
There is a high degree of variability in phenotype. FSHD1 and FSHD2 are clini-
cally indistinguishable. Patients present most frequently with the inability to lift 
arms overhead (82%) in the second or third decade of life. About 10% of patients 
notice facial weakness first, 8% of patients notice ankle dorsiflexion weakness first, 
and 5% notice pelvic girdle weakness first (these patients are often confused with 
Limb Girdle Muscular Dystrophy patients). Typically, facial, shoulder, and arm 
muscles are involved. Facial muscles, including orbicularis oculi and orbicularis 
oris with asymmetric involvement around the lips can occur. The mechanism of the 
asymmetry is unknown. Orofacial dysphagia without atrophy of the pharyngeal 
muscles can also occur. On MRI, tongue atrophy can be seen. The serratus anterior 
and rhomboids in the shoulder girdle (scapulo-) as well as biceps and triceps in 
the upper arms (humeral) are commonly involved. There is a lack of contractures 
around the weak muscles, which is often found in other forms of muscular dystro-
phy, such as Emery Dreyfus [9].
FSHD typically progresses from the upper to lower extremities. In the lower 
extremities, it progresses distal (TA, gastrocnemius) to proximal (quadriceps, 
hamstrings). There is involvement of the core muscles in an asymmetric pattern, 
including paraspinal muscles and abdominal muscles, leading to lumbar lordosis 
or camptocormia. The need for wheelchair occurs in 20% of patients in a bimodal 
distribution. In the severe infantile form with one to three D4Z4 units, the need for 
a wheelchair occurs in the second decade of life [9]. In other forms, it usually occurs 
when the patient is over age 50.
A Dutch study of 18% of their FSHD population showed that 74% of patients 
experienced pain for more than 4 days a month and 58% experienced pain for 4 or 
more days per week [9]. A French study showed that the cause of pain seemed to be 
exertion in 91% of patients or faulty posture due to weakness in 74% of patients [9]. 
Environmental temperature seemed to be a factor in 48% and humidity was a factor 
in 27% of patients. Pain management techniques, including analgesics, hot baths or 
showers, and massage provided only temporary relief. About 61% of patients report 
severe fatigue.
In the infantile form, large deletions resulting in fragments of only one to 
three D4Z4 repeats occur. Early onset cases are usually sporadic and are occa-
sionally diagnosed as Möbius syndrome. A Japanese study found an association 
with mental retardation and epilepsy in people with an early onset who are 
severely affected, although FSHD patients are usually mentally and cognitively 
normal [11].
3.1 Examination findings
Facial weakness is found in 94% of patients and is demonstrated by decreased 
brow furrow, inability to close their eyes fully or bury their eyelashes, or the 
inability to tense their platysma. In the chest wall, examination may reveal pectoral 
wasting, an exaggerated or inverted axillary crease, and 5% of patients will have 
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pectus excavatum. Shoulder girdle weakness occurs in 93% of cases and may be 
demonstrated by flattening of clavicular angle, rounding of shoulders, internal 
rotation of arms or triple hump sign (Figure 1), which is alternating muscle and 
bony landmarks on arm and shoulder. In the arms, one can see Popeye arm with 
wasting of biceps and triceps muscles and preservation of distal forearm muscles 
until late in disease. In the back, there is often lateral winging of the scapula with 
shoulder abduction or flexion (Figure 2). About 67% have ankle dorsiflexion 
weakness and 50% have pelvic girdle weakness. Patients often have a protuberant 
abdomen with demonstration of Beevor sign (Figure 3), which is asymmetric rise 
in umbilicus with abdominal tensing [2].
3.2 Cardiorespiratory involvement
About 0–13% of patients have restrictive lung disease due to loss of core 
strength. One percent of patients in a Dutch study were on nocturnal ventilatory 
support [12]. Risk factors for respiratory compromise include severe disease with 
wheelchair confinement, moderate to severe kyphoscoliosis, and presence of pectus 
excavatum.
Cardiomyopathy is not typical, although preclinical reduction of left ventricular 
function has been described. Asymptomatic supraventricular arrhythmias occur in 
~12% [12]. One study showed one-third of their subjects had right bundle branch 
block that did not progress over 8 years [12].
3.3 Ocular findings
Orbicularis oculi weakness causes incomplete lid closure (lagophthalmos), can 
lead to exposure keratitis and corneal scarring [2]. Eye drops, ointments, tap-
ing, or patches are not always successful in managing these problems. Peripheral 
telangiectasias of the retina occur in up to one-fourth of patients. Coats disease is an 
eye disease that can lead to retinal detachment and blindness. Although it usually 
occurs in males and is unilateral, in FSHD, it occurs in females and is bilateral. Coats 
disease affects less than 1% of FSHD patients and more commonly affects those 
with the smallest number of units (one to three D4Z4 units).
Figure 1. 
Triple hump sign: Alternating muscle and bony landmarks of shoulder girdle muscles. Source: Muscular 
Dystrophy Association.
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3.4 Ear findings
Asymptomatic loss of high-frequency hearing occurs in up to 65% of patients 
[2]. Hearing loss, requiring hearing aids affects patients with the smallest number 
of units (one to four D4Z4 units).
4. Diagnostic testing
Current guidelines call for genetic testing in all patients with clinical FSHD [2]. 
Labs that perform genetic testing for FSHD first test for D4Z4 contraction using 
a Southern blot, which has a sensitivity of 93% and specificity of 98%. Normal 
patients have fragments over 38 kb, but patients with FSHD1 have fragments 
10–38 kb, corresponding to 1–10 residual D4Z4 units. If this is negative, then the 
lab will determine if there is at least one A allele and less than 20% methylation to 
confirm FSHD2. Genetic testing for SMCHD1 gene is available; however the gene 
will only be expressed in a low methylation environment [8].
EMG shows small polyphasic motor units (myopathic units) with positive sharp 
waves or fibrillations. Muscle biopsy shows variation in fiber size, internal myo-
nuclei, degenerating and regenerating myofibers, and increased fibrosis or fatty 
Figure 2. 
Winged scapula (right). Source: Muscular Dystrophy Association.
Figure 3. 
Beevor sign: When the patients lift their head, their umbilicus displaces up and to the side.
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replacement of muscle. About 5–30% also show perivascular inflammatory infil-
trate, consisting of CD4 or CD8 cells. CK is modestly elevated at less than 10 times 
the upper limit of normal [2]. An MRI of the thigh shows hamstring involvement 
more than quadriceps involvement [9].
5. Treatment
Currently, there is no cure for FSHD. Scapulopexy (fascial or synthetic slings are 
used to improve scapular fixation to the thorax) or scapulodesis (scapula is fixed to 
the thoracic wall to produce a solid fusion) resulted in significant improvement in 
function, according to one study. Improvements were measured by ability to abduct 
the shoulder at 1 year and by patient-perceived improvement in the performance of 
activities of daily living [13].
Conservative management of FSHD includes referral to speech therapy for 
compensatory strategies for swallowing, ophthalmology consultation for eye 
issues, periodic hearing screenings, yearly EKGs, physical therapy, and occupa-
tional therapy and bracing. Abdominal supports and binders are useful for truncal 
weakness. The braces most commonly recommended for foot drop include fixed or 
hinged ankle-foot orthoses or floor reaction orthoses [9].
A Cochrane review of strength training and aerobic exercise training for muscle 
disease concluded that moderate-intensity strength training does not produce any 
benefit or harm in patients with FSHD [14].
5.1 New treatment literature review
5.1.1 Losmapimod
Researchers looked into preventing expression of DUX4 mRNA [15]. Past research 
showed agonists of the β-2 adrenergic receptor suppress DUX4 expression by activat-
ing adenylate cyclase to increase cAMP levels. In vitro experiments demonstrate that 
clinically advanced p38 inhibitors suppress DUX4 expression in FSHD type 1 and 2 
myoblasts. Individual small interfering RNA-mediated knockdown of either p38α or 
p38β suppresses DUX4 expression. p38 inhibitors effectively suppress DUX4 expres-
sion in a mouse xenograft model of human FSHD gene regulation. These data support 
the repurposing of existing clinical p38 inhibitors as potential therapeutics for FSHD.
p38α and p38β isoforms each independently contribute to DUX4 expression, so 
p38 isoform-selective inhibitors may balance efficacy and safety in skeletal muscle.
Losmapimod inhibits enzymes p38α/β mitogen-activated protein kinases 
(MAPKs). It has the drawback that p38 kinase inhibition could impair myogenesis 
by impairing myotube formation. However, GlaxoSmithKline clinical trials showed 
that losmapimod was generally well tolerated in over 3500 subjects. Two clinical 
trials of losmapimod for treatment of FSHD are going on at the time this chapter 
was written. ReDUX4 is evaluating drug efficacy in a randomized controlled phase 
IIb clinical trial with an estimated study completion date of August 2020. A phase 
II open-label clinical trial in the Netherlands, with an estimated study completion 
date of January 2021 is also ongoing at the time this chapter was written.
5.1.2 Resolaris
ATYR1940 (Resolaris) is based on a protein naturally secreted from muscle 
(resokine) that may act to decrease T-cell activation against muscle [16]. Quality 
of life and muscle strength of patients treated with Resolaris improved compared 
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to those on placebo, as assessed by individualized neuromuscular quality of life 
(INQoL) and manual muscle testing (MMT) scores. The phase 1/2 trial was com-
pleted in March of 2017. Results showed no significant trend of worsening in MMT 
or INQoL assessment scores. However, there was a low sample size of nine with 
three drop outs. The results of a phase 1b/2 trial of 18 patients with LGMD2B and 
FSHD showed that Resolaris did not suppress circulating immune cells and muscle 
function by MMT at 14 weeks improved in 50% of FSHD patients. Participants 
maintained or increased their MMT and INQoL scores at 24 and 36 weeks.
5.1.3 Decoy nucleic acid
A patented decoy nucleic acid can inhibit DUX4-mediated gene activation by 
binding to the DNA-binding site of the DUX4 transcription factor protein [17]. AAV 
vectors carrying in their genome two DUX4-binding sites injected in TA muscles of 
mice also receiving a DUX4-coding plasmid via electron transfer. In a study, AAV 
carrying the decoy oligonucleotide (AAV D3) significantly decreases DUX4 target 
gene (mTm7sf4) expression as compared to a control AAV. They concluded that 
AAV with a DUX4 decoy can inhibit DUX4 expression, making it a future treatment 
possibility for FSHD patients. DUX4 mRNAs observed in muscle and stem cells are 
heterogeneous, which can make targeting difficult.
5.1.4 Antisense oligonucleotides
The use of antisense oligonucleotides (AOs) targeting the DUX4 mRNA may 
interfere either with transcript cleavage/polyadenylation or intron splicing [18]. 
DUX4-targeted ASOs suppressed the atrophic FSHD myotube phenotype. The 
ASOs were not shown to improve the disorganized FSHD myotube phenotype, 
which could be caused by DUX4c over-expression. Therefore, DUX4c might consti-
tute another therapeutic target in FSHD.
5.1.5 Electrical stimulation
In a French study, electrical stimulation was performed to stimulate weak 
muscles with the goal of strengthening them [19]. They used an HVPG stimulator 
(Elettronica Pagani, Performer 982, Class Type BF, S/N:181, 2004, Supplier: Libor 
Medical Products, Ankara/Turkey, Manufacturer: Medical Expo Paderno Dugnano, 
Italy), using monophasic wave type (twin peak pulse) via surface electrodes. The 
pulse frequency of the device was 2–100 Hz, voltage output was 0–500 V, and pulse 
duration was 200 μs. They used a pulse frequency of 50 Hz for optimal contraction. 
Four electrodes were placed around the muscle and current intensity was increased 
up to significant contraction. Duty cycle was set at 5 seconds on and 10 seconds off, 
during 10 minutes of stimulation of each muscle. This was applied 3 times a week, 
for 8 weeks. Electrostimulation was effective in increasing the strengths of the 
deltoid and quadriceps femoris muscles. Muscle strength of the deltoid was higher 
in the electrical stimulation group, and the difference between the groups was 
maintained in the follow-up period (p < 0.05). Additionally, the electrical stimula-
tion group presented more obvious overall improvements than the exercise therapy 
group according to muscle strength, endurance, and timed performance tests.
5.1.6 Ace-083
ACE-083 binds to and inhibits select proteins in the TGF-beta protein superfam-
ily, namely activins and myostatin, which reduce muscle growth [20]. If a person 
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stops exercising, the muscles gradually reduce in size, due to the function of activins 
and myostatin, among other factors. Inhibiting the TGF-beta family reduces or 
slows this muscle breakdown. The researchers looked into whether this can be 
helpful for patients with Charcot–Marie-Tooth (CMT) or FSHD. However, phase 
2 clinical trials showed a lack of efficacy, so Acceleron halted the development of 
ACE-083 for FSHD. Trials for CMT were not halted.
6. Conclusion
Facioscapulohumeral muscular dystrophy is a disease with no cure; however, 
current research is promising for a cure in the near future. Technologies in genetic 
editing show particular promise in the field of muscular dystrophy. Molecular 
mechanisms of genetic diseases, even those with known mechanisms, are often-
times much more complex than initially thought. Discoveries regarding transcrip-
tion modulators have proven particularly useful in research to find treatments for 
muscular dystrophies. Given recent advances in these areas, the future appears 
bright for patients with muscular dystrophy.
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